6 Jul 2017 07:00
Realm Therapeutics plc
("Realm Therapeutics", "Realm" or the "Company")
PR013 Demonstrates Reduction in Allergic Conjunctivitis Inflammation Comparable to
Prednisolone (1%) in Clinically Relevant Preclinical Model
Data to be presented at upcoming World Congress on Inflammation
6 July 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that the Company will present a poster at the 2017 World Congress on Inflammation being held 8-12 July in London, England.
The poster presentation will highlight the significant efficacy and safety of PR013, a novel anti-inflammatory / immunomodulatory topical ocular solution in development for Allergic Conjunctivitis (AC). The Company remains on track to submit an IND for PR013 in Q3 of this year and start a Phase II clinical trial by the end of the year.
AC affects up to 40% of the US population and up to 20% of the population of Europe and Japan, including paediatrics. For approximately 30% of AC patients who do not adequately respond to the current standard of care, PR013 has the potential to represent a novel therapeutic alternative.
Details of the presentation are as follows:
Title: PR013 Reduces Symptoms of Allergic Conjunctivitis in the Murine CAC™ Model Comparable to Prednisolone (1%) and Demonstrates Excellent Safety in Repeat-Dose Ocular Tolerability Studies
Presenter: Mark Sampson, Ph.D., Vice President of Research and Development at Realm Therapeutics
Date/Time: Sunday, 9 July 2017 at 17:45 BST - Hilton London Metropole
The poster will be made available on the Company's website, www.realmtx.com following the presentation.
Enquiries:
Realm Therapeutics plc | +44 (0) 20 3727 1000 |
Alex Martin, Chief Executive Officer | |
Marella Thorell, Chief Financial Officer and Chief Operating Officer | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Mo Noonan | |
N+1 Singer (Nominated Adviser and Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell / Lauren Kettle |
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.
Forward looking statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.